NCT05265091进行中（未招募）1 期
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 414
- 试验地点
- 1
- 主要终点
- Phase I: Dose limiting toxicities (DLT)
研究概览
简要总结
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes
详细描述
This is an open, multicentre phase I/II study. To evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic properties and efficacy of KL590586 in patients with advanced NSCLC, MTC and other solid tumours carrying a RET fusion or mutation gene. Phase I of this study includes a dose-escalation phase and a dose-expansion phase (as needed), which will focus on exploring MTD and/or RP2D of KL590586 in patients with advanced solid tumours; Phase II will assess the efficacy and safety of KL590586 in different cohorts (NSCLC, MTC and other tumour types carrying RET fusions or mutations) of solid tumour patients at the RP2D dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Stage I: locally advanced or metastatic solid tumors that are pathologically diagnosed without standard treatment or intolerant to standard treatments
- •Stage II: locally advanced or metastatic NSCLC, MTC or other solid tumors confirmed by pathology
- •There is at least one measurable target lesion that meets RECIST v1.1 or RANO (only for brain tumor lesions)
- •Age > or = 18 years old at the time of signing the informed consent form, regardless of gender
- •Within 14 days before the first administration of the study treatment, the Eastern Cooperative Oncology Group (ECOG) performance status score was 0 or 1, and there was no sudden deterioration, and the expected survival time was > or = 3 months
- •Sufficient organ and bone marrow function (without receiving blood transfusion, erythropoietin, recombinant human thrombopoietin or colony stimulating factor therapy, renal replacement therapy, etc. within 7 days before the examination, the laboratory examination meets the following conditions Regulations): a) Blood routine: absolute neutrophil count (ANC) > or = 1.0×10^9/L; platelet count (PLT) > or = 75×10^9/L; hemoglobin concentration > or = 9.0 g/dl; b) Liver function: AST and ALT < or = 2.5×upper limit of normal (ULN), TBIL< or = 1.5×ULN; for patients with liver metastasis or primary biliary tract tumors, ALT and AST < or = 5×ULN; for liver cancer, liver metastasis or Gil Patients with Gilbert's syndrome, TBIL < or = 3×ULN; c) Renal function: serum creatinine (Cr) < or = 1.5×ULN or creatinine clearance > or = 40 ml/min (using the standard Cockcroft-Gault formula); d) Coagulation function: International normalized ratio (INR), activated partial thromboplastin time (APTT) and prothrombin time (PT) < or = 1.5×ULN;
- •Able to understand and voluntarily sign an informed consent form, and be able to comply with the visit and related procedures stipulated in the plan
排除标准
- •There are known major driver gene changes other than RET. For example, NSCLC carrying targeted mutations such as EGFR, ALK, ROS1 or BRAF; colorectal cancer carrying mutations such as oncogenic KRAS, NRAS or BRAF. If the patient has a co-mutation, the investigator should discuss with the sponsor whether the patient can be included in the group
- •Symptomatic primary central nervous system (CNS) tumors, brain metastases, leptomeningeal carcinogenesis, or untreated spinal cord compression that the researchers believe require local intervention
- •People with other active malignant tumors (except for non-melanoma skin cancer in situ, cervical cancer in situ and other localized tumors that have been cured and have not recurred within 5 years)
- •Need to use drugs known to be potent inhibitors or inducers of CYP3A4, drugs known to prolong QTc, and the treatment cannot be terminated at least 14 days before the study drug is administered
- •Received the following anti-tumor treatments: a) The previous anti-tumor drug treatment (except immunotherapy or other antibody therapy) is less than 14 days or 5 half-lives (whichever is longer) from the first treatment with study drug; b) In Those who have received any immunotherapy or other antibody treatment within 28 days before the first study drug administration; c) Those who have received more than 30% of bone marrow radiation or wide-range radiotherapy within 28 days before the first study drug treatment (the patients receiving palliative radiotherapy are the first Within 7 days before receiving study drug treatment)
- •Received major surgical operations within 28 days before receiving the first study drug treatment (excluding operations such as central venous catheter placement, tumor biopsy, and gastric tube placement)
- •Those who have received other clinical trial drug treatment within 28 days before receiving the first study drug treatment
- •Any original symptoms that may interfere with the results of the study, including: any unrecovered toxicity above grade 1 of the CTCAE related to previous anti-tumor therapy (hair loss and grade 2 neuropathy related to previous platinum-based drug treatment, etc.) Except for chronic toxicity judged by the person
- •Patients with clinically active interstitial lung disease, active pneumonia, and radiation pneumonia requiring treatment, or those who have been found or suspected of having such diseases during the screening period
- •Poorly controlled pleural effusion, abdominal effusion, or pericardial effusion after intervention (such as drainage)
- •Any serious and/or uncontrolled comorbidities that may prevent the patient from participating in the study
- •Those who are known to be allergic to any component in the study drug prescription
- •Clinically significant active malabsorption syndrome or other diseases that may affect study drug administration and gastrointestinal absorption
- •Active hepatitis B (hepatitis B surface antigen is positive and HBV-DNA is higher than the upper limit of normal detection) or hepatitis C (hepatitis C antibody is positive and HCV-RNA is higher than the upper limit of normal detection); Human immunodeficiency virus (HIV) examination Positive or known acquired immunodeficiency syndrome (AIDS); Treponema pallidum antibody test is positive
- •Pregnant or breastfeeding women, fertility patients (regardless of male and female) who cannot take effective medical contraceptive measures during the study period and within 6 months after the last administration
- •Other situations where the researcher thinks it is inappropriate to participate in this research
研究组 & 干预措施
KL590586
Experimental
Multiple doses of KL590586 capsule
干预措施: KL590586 Capsule (Drug)
结局指标
主要结局
Phase I: Dose limiting toxicities (DLT)
时间窗: From date of initial dose until up to 28 days for treatment
Incidence rate of dose limiting toxicities (DLT)
Phase II: ORR
时间窗: Approximately 12 months
Objective response rate (ORR)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase I/II Clinical Trial of LBL-015 for InjectionAdvanced Malignant TumorNCT05107011Nanjing Leads Biolabs Co.,Ltd25
进行中（未招募）
1 期
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaNon Hodgkin LymphomaAcute Lymphoblastic LeukemiaNCT04606433Sichuan Baili Pharmaceutical Co., Ltd.47
终止
1 期
To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05879627Bio-Thera Solutions93
招募中
1 期
New Formulation Study of Inupadenant (EOS100850) in Patients With CancerSolid Tumor, AdultNCT05117177iTeos Therapeutics64
已完成
1 期
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin LymphomaRelapsed or Refractory Classical Hodgkin LymphomaNCT05216835AstraZeneca45